Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

NCT02362230 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

26

Enrollment

OTHER

Sponsor class

Stopped Difficulty accruing subjects the study accrual was closed

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Icotinib

Sponsor

Sun Yat-sen University